re: Ann: HeartWare Announces Date for FDA Adv...
http://www.zacks.com/stock/news/71795/Thoratec+Downgraded+to+Neutral+-+Analyst+Blog However, there is no imminent competitive threat from HeartWare in the DT segment as its product is not expected to be launched till 2015. It appears that the hyper-growth phase enjoyed by Thoratec has stabilized to more normalized growth. Thoratec has demonstrated expertise in product development even as HeartWare is expected to close the technological gap.
HIN Price at posting:
$1.80 Sentiment: LT Buy Disclosure: Held
